Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
Andres PovedaBradley J Monk

Abstract

OVA-301 is a large randomized trial that showed superiority of trabectedin plus pegylated liposomal doxorubicin (PLD) over PLD alone in relapsed ovarian cancer. The optimal management of patients with partially platinum-sensitive relapse [6-12 months platinum-free interval (PFI)] is unclear. within OVA-301, we therefore now report on the outcomes for the 214 cases in this subgroup. Trabectedin/PLD resulted in a 35% risk reduction of disease progression (DP) or death [hazard ratio (HR) = 0.65, 95% confidence interval (CI), 0.45-0.92; P = 0.0152; median progression-free survival (PFS) 7.4 versus 5.5 months], and a significant 41% decrease in the risk of death (HR = 0.59; 95% CI, 0.43-0.82; P = 0.0015; median survival 23.0 versus 17.1 months). The safety of trabectedin/PLD in this subset mimicked that of the overall population. Similar proportions of patients received subsequent therapy in each arm (76% versus 77%), although patients in the trabectedin/PLD arm had a slightly lower proportion of further platinum (49% versus 55%). Importantly, patients in the trabectedin/PLD arm survived significantly longer after subsequent platinum (HR = 0.63; P = 0.0357; median 13.3 versus 9.8 months). This hypothesis-generating analysis demonstr...Continue Reading

References

Jun 5, 2003·Cancer Chemotherapy and Pharmacology·Daniela MecoRiccardo Riccardi
Mar 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cristiana SessaNicoletta Colombo
Apr 13, 2005·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·H T SeeJ J Kavanagh
May 24, 2006·Seminars in Oncology·Jacobus Pfisterer, Jonathan A Ledermann
Sep 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jacobus PfistererUNKNOWN EORTC GCG
Jun 15, 2007·Critical Reviews in Oncology/hematology·Nicoletta Colombo, Martin Gore
May 24, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M von MehrenR B Cohen
Aug 30, 2008·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·A GadducciA R Genazzani
Oct 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jean-Yves BlayAxel Le Cesne
Dec 31, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C SessaL Gianni
Jun 27, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J M Del CampoUNKNOWN Yondelis Ovarian Cancer Group
Jan 9, 2010·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Bradley J Monk, Robert L Coleman
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bradley J MonkAndrés M Poveda
Jul 21, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S B KayeA Poveda

❮ Previous
Next ❯

Citations

Nov 18, 2010·Archives of Gynecology and Obstetrics·Ansgar Brüning, Ioannis Mylonas
Mar 8, 2013·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·A González MartínA Poveda Velasco
Jul 21, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S B KayeA Poveda
Nov 10, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C Sessa, M D'Incalci
Jul 8, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J SehouliA González-Martín
Oct 23, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J A LedermannUNKNOWN ESMO Guidelines Working Group
Dec 7, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P HarterA du Bois
Dec 7, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A González-Martín
Nov 15, 2013·Future Oncology·Jalid SehouliDomenica Lorusso
Oct 4, 2012·Future Oncology·Klaus H BaumannAndreas du Bois
Oct 22, 2013·Cancer Chemotherapy and Pharmacology·Anne FloquetSimone Mathoulin-Pélissier
May 30, 2014·Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquée, Nutrition Et Métabolisme·Carla M M PradoMichael B Sawyer
Oct 30, 2014·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·A Gonzalez-MartínL Vidal
Nov 3, 2011·Current Oncology Reports·Marcia Hall, Gordon Rustin
Jul 25, 2015·Expert Opinion on Investigational Drugs·Claudia MarchettiPierluigi Benedetti Panici
Apr 17, 2012·Current Opinion in Pharmacology·John A Hartley, Daniel Hochhauser
Apr 12, 2013·Journal of Drug Delivery·Carmela PisanoSandro Pignata
Jun 24, 2015·Women's Health·Mark R OpenshawHani Gabra
Mar 15, 2015·Japanese Journal of Clinical Oncology·Koji MatsumotoNobuo Yaegashi
Jan 14, 2016·EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [et Al.]·Nicoletta Colombo
May 4, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Pujade-Lauraine, P Combe
Aug 16, 2016·SpringerPlus·Gonzalo H Giornelli
Feb 1, 2017·Expert Opinion on Pharmacotherapy·Eleonora Teplinsky, Thomas J Herzog
Dec 13, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S PignataF Heitz
Oct 13, 2017·Future Oncology·Andrés Poveda, Christian Marth
May 6, 2011·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Nicoletta Colombo
Jan 26, 2016·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Laura MansiElsa Kalbacher
Jan 9, 2016·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Gilles FreyerAliki Taylor
Jun 3, 2017·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Gabriella FerrandinaGiovanni Scambia
Mar 27, 2019·Cancers·Ainhoa MadariagaAmit M Oza
Mar 20, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M BuechelK N Moore
Feb 1, 2011·Journal of Gynecologic Oncology·Dong Hoon SuhSoon-Beom Kang
Jul 10, 2013·The Cochrane Database of Systematic Reviews·Theresa A LawrieJo Morrison
Feb 8, 2019·Minerva ginecologica·John SyriosUNKNOWN GU Working Group of the Hellenic Oncology Research Group (HORG)
Sep 21, 2019·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Alice BergaminiGiorgia Mangili
Nov 17, 2016·Oncotarget·Luigi RossiFederica Tomao

❮ Previous
Next ❯

Software Mentioned

CALYPSO

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.